Basement membrane heparan sulfate proteoglycan from the L2 rat yolk sac carcinoma  by Fenger, Mogens et al.
Volume 173, number 1 FEBS 1612 July 1984 
Basement membrane heparan sulfate proteoglycan from the L2 
rat yolk sac carcinoma 
Mogens Fenger, Ulla Wewer* and Reidar Albrechtsen* 
The Department of Clinical Chemistry, Rigshospitalet, Blegdamsvej 9 and *The University Institute of Pathological 
Anatomy, DK-2100 Copenhagen, D mark 
Received 26 May 1984; revised version received 18 May 1984 
Heparan sulfate proteoglycan from the L2 rat yolk sac carcinoma has been purified and partially 
characterized. The proteoglycan has an apparent Mr of 750000, 35% of which represents the core protein. 
The core protein seems to be homogeneous, whereas the heparan sulfate chains are heterogeneous with 
an M, of about 50000-70000, with 30% of the glucosamine being N-sulfated. Antibodies raised against 
the core protein of the heparan sulfate proteoglycan reacted with basement membranes of various rat and 
human tissue. 
Basement membrane Proteoglycan 
1. INTRODUCTION 
Heparan sulfate proteoglycans (HS-PC) are in- 
tegral components of the basement membrane as 
are laminin [ 11, type IV collagen [2], entactin [3], 
and nidogen [4]. Basement membrane HS-PC have 
in varying degrees been purified and characterized 
from the EHS-tumor [5], the PYS-2 [6] and the 
M 1536-B3 [7] parietal endoderm cell lines. In addi- 
tion, HS-PC have been isolated from authentic 
basement membrane of the rat kidney [8]. 
The L2 rat yolk sac carcinoma has been shown 
to produce laminin, type IV collagen and entactin 
[9], and it also seems to be a unique source of 
chondroitin sulfate proteoglycan [lo]. 
Here we report on the purification procedure 
and partial characterization of a basement mem- 
brane HS-PC from the L2 rat yolk sac carcinoma. 
2. MATERIALS AND METHODS 
2.1. Heparan sulfate proteoglycan from ascites 
Ascites fluid was collected from Lewis rats in- 
jected intraperitoneally with cells from the L2 yolk 
sac carcinoma cell line [9]. Aprotinin (NOVO A/S, 
Heparan sulfate Yolk sac carcinoma 
Denmark) and phenylmethylsulfonyl fluoride 
(PMSF, Sigma, St. Louis, MO) were added to 
500 KIE/ml and 1 mM final concentrations, 
respectively. The ascites fluid was cleared for cells 
and debris by centrifugation and dialyzed against 
several changes of water containing aprotinin and 
PMSF. NaCl was added to a final concentration of 
0.35 M and the glycosaminoglycans (GAG) were 
precipitated with 10 ml 6% (w/v) cetyltrimethyl- 
ammonium bromide (CTAB) per 150 ml ascites at 
room temperature overnight. The precipitate was 
collected by centrifugation, solubilized in a 5: 1 
mixture of 2 M NaCl and methanol, and the GAG 
was further precipitated by 3 vols of 96% ethanol. 
The GAG was finally solubilized in 0.1 or 0.5 M 
NaCl in phosphate buffer (pH 7.4), chromato- 
graphed on Sepharose CLdB, and, after extensive 
digestion [ 111 by chondroitinase ABC (Seikagaku, 
Japan), on Sepharose CL-6B and 4B (Pharmacia, 
Uppsala). All chemicals used were of reagent grade 
or the best quality available. 
2.2. Antibodies to heparan sulfate proteoglycan 
Two rabbits were immunized with 100 pg of the 
purified HS-PC emulsified in Freund’s complete 
adjuvants as in [12]. The reactivity of the antisera 
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to basement membranes was investigated on 
ethanol :acetic acid- or formalin-fixed paraffin- 
embedded tissues, using the unlabeled antibody 
peroxidase-antiperoxidase (PAP) technique [ 131. 
2.3. Other methods 
Uranic acid [14] and N-sulfate [15] were deter- 
mined as described. Amino acid composition and 
hexosamine content were determined on an LKB 
amino acid analyzer. Iodination of the pro- 
teoglycans was performed by the Bolton-Hunter 
procedure [ 161. Radiochemicals were purchased 
from New England Nuclear. The enzyme im- 
munoassay, ELISA [12], was used to test for the 
presence of laminin, type IV collagen, entactin, 
and fibronectin. 
3. RESULTS 
3.1. Isolation and identification of heparan 
sulfate proteoglycan 
HS-PG was isolated from ascites fluid and from 
extracts of solid tumor tissue of the L2 rat yolk sac 
carcinoma. The purification procedure included 
CTAB and ethanol precipitations, treatment with 
chondroitinase ABC, and gel filtration on 
Sepharose CL-6B and 4B (fig.l-3). The yield of 
HS-PG was approx. 5 mg/l ascites. 
The material obtained (indicated by bar in fig.3) 
was identified as HS-PG. Firstly, the N-sulfate 
content (fig.3) paralleled the uranic acid content. 
Secondly, a small aliquot was labelled with 1251 and 
chromatographed on Sepharose CL-6B. The 
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Fig.1. Gel filtration on a 2.6 x 96 cm column of 
Sepharose CLdB in 0.1 M phosphate buffer (pH 7.4), 
0.1 M NaCl of CTAB-precipitated material from L2 
ascites fluid; 9.5-ml fractions were collected at room 
temperature ata flow rate of 25 ml/h. V, and VT, void 
volume and total volume, respectively. 
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Fig.2. The pool indicated by the bar in fig.1 was 
rechromatographed after extensive digestion with 
chondroitinase ABC. Column and chromatographic 
conditions as in fig.1. 
iodinated material eluted near the void volume was 
treated with 1 unit heparinase (Seikagaku) for 20 h 
at 37°C [17] and subsequently reapplied on the 
same Sepharose CLdB column. As shown in fig.4, 
all iodinated protein was eluted near the total 
volume of the column, indicating that all the GAG 
was susceptible to heparinase. Thirdly, a “‘1 ali- 
quot was treated with 2 M NaOH at 37°C for 20 h 
and chromatographed on 1.1 x 96 cm AcA 34 
(LKB). A symmetrical 1251 peak eluted with Kav = 
0.32 (fig.5), indicating a homogeneous core pro- 
tein and showing that the side chains probably 
were linked to the hydroxyl group of serine 
through xylose [ 181. Furthermore, this elution pro- 
file corresponds to a molecular mass of approx. 
200 kDa. Finally, no galactosamine could be de- 
tected (table 1). Laminin, type IV collagen, entac- 
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Fig.3. Gel filtration on a 2.6 x 96 cm column of 
Sepharose 4B of pool II from fig.2. Chromatographic 
conditions as in fig. 1. 
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Fig.4. Chromatography on a 1.1 x 93 cm column of 
Sepharose CL-6B in 0.1 M phosphate buffer (pH 7.4), 
0.5 M NaCl of ‘ZSI-labelled material from fig.3 before 
(o--o) and after (M) digestion with heparinase. 
The column was eluted at room temperature with a flow 
rate of IS ml/h, and 1.2 ml fractions collected. V, and 
Vr, void volume and total volume, respectively. 
tin, and fibronectin did not seem to contaminate 
the HS-PG as shown immunochemically by the 
ELISA assays, and by the amino acid analyses, 
which characteristically did not reveal any 
cysteine. 
x IO-‘cpm 
30- 
lVo 
!1 
“1 
1 
. 
20- 
1 \ . . 
1 I . 
lo- i \ 
i i 
i 
i 
?\ 
/ ‘.. x...*_._ _ 
!...-+I.... ’ 
24 30 LO 50 60 ?b 12 
FRACTION NUMBER 
Fig.5. Chromatography on 1.1 x 96 cm column of AcA 
34 of iodinated HS-PG treated with 2 M NaOH for 20 h 
at 37°C. Chromatographic conditions as in fig.4. 
Table 1 
Composition of the L2 HS-PC compared with the BMr 
HS-PG from the EHS-tumor [5] and with the L2 CS-PG 
WI 
Residues/1000 
L2 EHS L2 
HS-PG HS-PG CS-PG 
Aspartic acid 
Threonine 
Serine 
Glutamic acid 
Proline 
Glycine 
Alanine 
Cysteine 
Valine 
Methionine 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Histidine 
Lysine 
Arginine 
GluNH2” 
GalNH2 
N-Sulfate 
74 81 88 
42 68 34 
101 84 183 
173 154 116 
36 81 61 
139 106 185 
75 70 68 
Nil ? Nil 
79 63 72 
ND 13 10 
49 26 18 
66 81 20 
24 24 ND 
24 32 43 
39 32 61 
37 29 22 
42 54 15 
369 372 82 
Nil 24 2287 
111 
’ The number of hexosamine residues are expressed per 
1000 amino acid residues 
ND, not determined 
Preliminary results indicate that a similar, if not 
identical, HS-PG was isolated from solid tumor 
tissue extracted with 4 M guanidine-HCl and 1% 
Triton X-100. 
3.2. Characterization of the isolated heparan 
sulfate proteoglycan 
The overall size of the HS-PG was roughly 
estimated to be 750 kDa based on its elution posi- 
tion (fig.l-3) on Sepharose CLdB and 4B [5]. 
The core protein accounted for 35% of the HS- 
PG, as judged by the amino acid analyses. This 
corresponds to a molecular mass of 250 kDa, 
which is consistent with the elution profile on the 
AcA 34 column (fig.5), provided that the core pro- 
tein attains a globular structure after alkali treat- 
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ment. However, the fact that it was eluted in the 
total volume of the Sepharose CL-6B (fig.4) sug- 
gests a lower molecular mass of the core protein. 
This discrepancy might reflect the presence in the 
heparinase preparation of proteolytic activity 
which could not be detected using, for example, 
iodinated albumin as a substrate (not shown). 
To define further the size of the heparan sulfate 
chains (HS-chains), the HS-PG was treated with 
NaB3H4 (11 Ci/mmol) in 0.5 M NaOH at 37°C for 
20 h. The liberated HS-chains were chromatog- 
raphed on AcA 44 (LKB) and Sepharose 4B. The 
HS-chains show molecular size heterogeneity, as 
can be seen from fig.6. Most of the chains were 
eluted in the void volume of AcA 44, indicating a 
molecular mass above 50 kDa [ 191. The HS-chains 
were included in the Sepharose 4B column and 
eluted in two main groups with K,, = 0.54 and 
0.65, respectively. The exact molecular mass could 
not be determined because of a lack of suitable 
standards, but by calculating the specific activity 
of the labelled HS-chains (mol 3H/mmol uranic 
acid), the molecular mass could be estimated at 
50-70 kDa. 
K AV 
Fig.6. 3H-Labelled HS-chains were chromatographed on 
a 1 .l x 96 cm column of AcA 44 (C--O), and on a 
1 .l x 90 cm column of Sepharose 4B (M). 
Chromatographic conditions as in fig.4. 
Fig.7. Immunostaining using antisera (dilution 
1: 100-200) raised against the isolated HS-PG. Note the 
intense staining reaction localized to basement 
membranes. (A) The L2 yolk sac carcinoma (X 260). (B) 
Mucosal epithelium of the normal rat tongue (X 260). 
(C) The Reichert’s membrane of the parietal yolk sac 
endoderm of normal developing rat embryo (X 250). 
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The antisera raised against the purified HS-PG 
were applied in immunohistochemical investiga- 
tions. A moderate to intense immunostaining of 
the extracellular matrix of the rat yolk sac car- 
cinoma was seen. A variety of normal rat tissues 
(salivary gland, tongue, tracheal tissue, intestine, 
kidney, skin) exhibited an intense staining reaction 
of the basement membranes (fig.7). Immunostain- 
ing of basement membranes of the rat embryo was 
likewise observed, with the Reichert’s membrane 
being particularly positive (fig.7). In addition, 
cross-reactivity to basement membranes of human 
tissue was demonstrated. 
4. DISCUSSION 
A number of different populations of HS-PG 
have been identified, some of which are consti- 
tuents of basement membranes [20]. Although the 
major proteoglycan produced by the L2 rat yolk 
sac carcinoma is chondroitin sulfate proteoglycan 
[lo], this study shows that small amounts of HS- 
PG also are synthesized by this tumor. 
The L2 HS-PG seems to share some 
characteristics (e.g., molecular mass, amino acid 
composition, and basement membrane localiza- 
tion) with the BMi, which was purified from the 
EHS-tumor as in [5]; but further studies are need- 
ed to define, for instance, their immunological 
similarities. 
Our immunostaining results demonstrate that 
antisera raised against the L2 HS-PG react 
distinctly with authentic basement membranes, in 
a manner similar to that described for antisera 
against BMi [21,22]. The fact that the antibodies 
also reacted with human tissue indicates the 
usefulness of such antisera in studies of various 
normal and pathological states. 
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